Lilly to begin pragmatic study of neutralizing antibody bamlanivimab (LY-CoV555) for COVID-19 in New Mexico.

Eli Lilly and Company announced plans to begin a new pragmatic study of bamlanivimab (LY-CoV555) in high-risk patients with COVID-19, in collaboration with major local institutions in the state of New Mexico . Conducting the study in New Mexico will allow for the collection of data on the effectiveness and safety of bamlanivimab in a real-world setting that includes a diverse population and spans both rural and urban environments. Bamlanivimab recently received Emergency Use Authorization (EUA) by the FDA for the treatment of mild to moderate COVID-19 patients who are at high risk for progressing to severe COVID-19 and/or hospitalization. The study will begin in the coming weeks and will evaluate the effectiveness of bamlanivimab in reducing COVID-19 hospitalizations in a high-risk population. Under the study design, a variety of infusion settings will be utilized across the state, allowing access to multiple diverse communities – including Native American communities. As part of this study, Lilly will employ its unique mobile research units used successfully in other studies. These units include a custom retrofitted recreational vehicle (RV) solution to support mobile labs and clinical trial material preparation, along with a support vehicle to deliver all clinical trial supplies needed to create an on-site infusion clinic for patients who may otherwise not be able to participate in a clinical study due to lack of access.